Title of Invention

"NITROGENATED HETEROCYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME"

Abstract

The present invention relates to novel compounds having a xanthine oxidase inhibitory effect and an uricosuric effect and pharmaceutical compositions comprising the same as an active ingredient. That is, the present invention relates nitrogen-containing heterocyclic compounds represented by the following general formula (I): wherein Y1 represents N or C(R4); Y2 represents N or C(R5); R4 and R5 independently represent an alkyl group, a hydrogen atom etc. ; one of R1 and R2 represents an optionally substituted aryl group, an alkoxy group or an optionally substituted heterocyclic group; the other of R1 and R2 represents a haloalkyl group, a cyanogroup, a halogen atom etc. ; and R3 represents a 5-tetrazolyl group or a carboxy group, and pharmaceutically acceptable salts thereof, and pharmaceutical compositions comprising the same as an active ingredient.

Full Text

DESCRIPTION NITROGENATED HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Technical Field [0001] The present invention relates to nitrogen-containing heterocyclic compounds and pharmaceutical compositions containing the same. More particularly, the present invention relates to nitrogen-containing heterocyclic compounds having a xanthine oxidase inhibitory effeict and an uricosuric effect and pharmaceutical compositions containing the same. Background Art [0002] The major causes of hyperuricemia are increased production and decreased excretion of uric acid. The former is mainly caused by overproduction of uric acid by xanthine oxidase (hereinafter also referred to as X.O.). On the other hand, the latter is increased renal tubular reabsorption of uric acid and the main mechanism is upregulation of human uric acid transporter (hereinafter also referred to as URAT1). Since uric acid is slightly soluble in water, that causes hyperuricemia. When uric acid in blood gets excessive, crystalline uric acid precipitates in the joints and so on and that causes an acute attack of arthritis (gout) or chronic changes in bones and joints. Furthermore, complications such as urinary calculi and renal insufficiency ( gouty kidney) become a problem. [0003] Currently, as therapeutic agents for gout and hyperuricemia, alloprinol, a X.O. inhibitor, is widely used. In addition, other therapeutic agents for hyperuricemia having a X.O. inhibitory effect are disclosed in Patent references 1 to 4. Benzbromarone having an inhibitory effect of uric acid reabsorption (an uricosuric effect) is also used. As another agent, probenecid is illustrated, but it is not frequently used due to its weak activity. In addition, biaryl compounds or diaryl ether compounds described in Patent reference 5 are reported as agents having an uricosuric effect. [Patent reference 1] Japanese Patent No.3399559 specification. [Patent reference 2] Japanese Patent No.3220987 specification. [Patent reference 3] Japanese Patent Publication No.2002-105067 gazette. [Patent reference 4] International Publication NO.W003/064410 pamphlet. [Patent reference 5] Japanese Patent Publication No.2000-001431 gazette. Disclosure of the invention Problem that the invention aims to solve [0004] However, regarding allopurlnol of a X.O. inhibitor, oxypurinol, a methabolic product, can be accumulated in a body, and adverse effects such as rash, deterioration of renal function, hepatitis and the like have been reported, and thus, it is not always an easy-to-use agent. In addition, regarding benzbromarone which has an inhibitory effect of uric acid reabsorption (an uricosuric effect), severe adverse effects such as fulminant hepatitis are reported and calculi can be caused. Therefore, proper limited use is required, and it is not always an easy-to-use agent. On the other hand, clinical benefits of the therapeutic agents for hyperuricemia having a X.O. inhibitory effect described in Patent references 1 to 4 are still uncertain. Pharmacological effects of the biaryl compounds or diary ether compounds described in Patent reference 5 seem weaker than existing products. Most of therapeutic agents in the technical field have been sold for a few decades, and in order to broaden treatment options, a new therapeutic agent has been still desired in the medical field. [0005] Therefore , the objective of the present invention is to provide a novel compound having a X.O. inhibitory effect and an uricosuric effect, and a pharmaceutical composition comprising as an active ingredient the same. Means to solve the problem [0006] The present inventors have studied earnestly to solve the above problem and finally found that a certain nitrogen-containing heterocyclic compound having a specific structure has a X. O. inhibitory effect and an uricosuric effect, thereby forming the basis of the present invention. [0007] That is, the present invention relates to: [1] a nitrogen-containing heterocyclic compound represented by the following general formula (I): [Chem.l] R1 (Formula Removed) wherein Y1 represents N or C(R4); Y2 represents N or C(R5); R4 and R5 independently represents an alkyl group which may have a halogen atom, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; one of R1 and R2 represents an haloalkyl group, a cyano group, a carbamoyl group or a halogen atom; the other of R1 and R2 represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring, an alkoxy group or a heterocyclic group selected from the group consisting of a thienyl, thiazolyl or pyrrolyl group which may be substituted by an alkyl group or a halogen atom; and R3 represents a 5-tetrazolyl group or a carboxy group; and with the proviso that when Y2 represents CR5, Y2 may form a benzene or pyridine ring which may have a haloalkyl group, a halogen atom, a cyano group or an alkoxy group as a substituent together with R2, and some of the neighboring substituents on the ring may form a ring, or a pharmaceutically acceptable salt thereof; [2] a nitrogen-containing heterocyclic compound as described in the above [1] represented by the following general formula (I-A) or (I-B): [Chem.2] (Formula Removed) wherein R4a and R5a independently represent a hydrogen atom or an alkyl group; one of Rla and R2a represents a haloalkyl group, a cyano group or a halogen atom; the other of Rla and R2a represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring, an alkoxy group or a heterocyclic group selec ted from the group consisting of a thienyl, thiazolyl or pyrrolyl group which may be substituted by an alkyl group or a halogen atom; and R3 represents a 5-tetrazolyl group or a carboxy group, or a pharmaceutically acceptable salt thereof; [3] a nitrogen-containing heterocyclic compound as described in the above [ 2 ] , wherein Rla represents a cyano group, or a pharmaceutically acceptable salt thereof; [4] a nitrogen-containing heterocyclic compound as described in the above [3 ] , wherein R2a represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring; an alkoxy group; or a thienyl group which may be substituted by an alkyl group or a halogen atom, or a pharmaceutically acceptable salt thereof; [5] a nitrogen-containing heterocyclic compound as described in any of the above [2] to [4] , wherein R3 represents a carboxy group, or a pharmaceutically acceptable salt thereof; [6] a nitrogen-containing heterocyclic compound as described in the above [ 1] represented by the following general formula (I-C): [Chem.4] (Formula Removed) wherein Y1C represents N or C(R4C); Y3 represents N or C(R9); R4C and R9 independently represent an alkyl group, a haloalkyl group, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; R1C represents a cyano group or a carbamoyl group; R6, R7 and R8 independently represent an alkyl group, a haloalkyl group, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; or any of R6, R7 and R8 may form a ring together with the neighboring substituent; and R3 represents a 5-tetrazolyl group or a carboxy group, or a pharmaceutically acceptable salt thereof; [7] a nitrogen-containing heterocyclic compound as described in the above [ 6 ] , wherein Rlc represents a cyano group , or a pharmaceutically acceptable salt thereof; [8] a nitrogen-containing heterocyclic compound as described in the above [ 6 ] or [ 7 ] , wherein R3 represents a carboxy group, or a pharmaceutically acceptable salt thereof; [9] a pharmaceutical composition comprising a nitrogen-containing heterocyclic compound as described in any of the above [1] to [8] or a pharmaceutically acceptable salt thereof as an active ingredient; [10] a pharmaceutical composition as described in the above [9], which is a xanthine oxidase inhibitor; [11] a pharmaceutical composition as described in the above [9] or [10], which is an uricosuric agent; [12] a pharmaceutical composition as described in any of the above [9] to [11], which is an agent for the treatment of gout or hyperuricemia; [13] a pharmaceutical composition as described in the above [9], which is an agent for the treatment of ischemic-reperfusion disorder, inflammatory disease, diabetes, cancer, arteriosclerosis or neurological disease; and the like. [0008] Furthermore, another pharmaceutical composition of the present invention is characterized in comprising as an active ingredient the above nitrogen-containing he terocyclic compound of the present invention or a pharmaceutically acceptable salt thereof. [0009] Definitions of substituents or the like used in the present specification are as follows. The term "aryl group" means a phenyl group, a naphthyl group, a biphenyl group or the like. The term "alkyl group" may be a straight-chained, branched or cyclic one, and the number of carbon atoms is not limited but preferably 1 to 12. An alkyl part of "alkoxy group" may be a straight-chained, branched or cyclic one, and the number of carbon atoms is not limited but preferably 1 to 12 similarly to the above alkyl group. [0010] The term "halogen atom" means a fluorine atom, a chlorine atom, a bromine atom or a iodine atom. The term "haloalkyl group" means the above alkyl group substituted by one or more (preferably 1 to 3) halogen atoms as defined above. In case that there are two or more halogen atoms , they may be different. Effect of the invention [0011] Nitrogen-containing heterocyclic compounds of the present invention or pharmaceutically acceptable salts thereof are compounds which have a X.O. inhibitory effect and an uricosuric effect. Pharmaceutical compositions of the present invention comprising these compounds as an active ingredient can be expected to be useful as an agent for the treatment of gout or hyperuricemia and for the treatment of various diseases such as ischemia-reperfusion disorder, inflammatory disease, diabetes, cancer, arteriosclerosis, neurological disease or the like. Best mode to operate the invention [0012] In case that a nitrogen-containing heterocyclic compound represented by the general formula (I) of the present invention is a nitrogen-containing heterocyclic compound represented by the above general formula (I-A) or (I-B), one of R1 and R2 is preferably a cyano group, and the other of R1 and R2 is preferably an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring, or an alkoxy group, or a thienyl group which may be substituted by an alkyl group or a halogen atom; and R1 is more preferably a cyano group. As the above aryl group, a phenyl group is more preferable. As R3, a carboxy group is preferable. [0013] In case that a nitrogen-containing heterocyclic compound represented by the general formula (I) of the present invention is a nitrogen-containing heterocyclic compound represented by the above general formula (I -C), R1C is preferably a cyano group. It is preferable that Ylc is C(R4C) and Y3 is C(R9) at the same time wherein R4C and R9 independently are a haloalkyl group, a hydrogen atom, a cyano group or an alkoxy group. As R3, a carboxy group is preferable. [0014] In nitrogen-containing heterocyclic compounds of the present invention, a pharmaceutically acceptable salt is not limited but includes , for example, salts with hydrochloric acid, sulfuric acid, phosphoric acid, nitric acid, acetic acid, propionic acid, succinic acid, glycolic acid, lactic acid, malic acid, oxalic acid, tartaric acid, citric acid, maleic acid, fumaric acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, ascorbic acid .and the like. Such a salt may be a hydrate, solvate or the like. [0015] A pharmaceutical composition of the present invention is characterized in comprising as an active ingredient a nitrogen-containing heterocyclic compound or a pharmaceutically acceptable salt thereof. The pharmaceutical compositions of the present invention are suitable as a xanthine oxidase inhibitor and/or an uricosuric agent and useful for the treatment of gout or hyperuricemia. [0016] In addition, since xanthine oxidase is focused as an enzyme related to active oxygen generation, the pharmaceutical compositions of the present invention are expected as an agent for the treatment of diseases associated with active oxygen generation such as ischemic-reperfusion injury, inflammatory disease, diabetes, cancer, arteriosclerosis, neurological disease or the like. [0017] In the pharmaceutical compositions of the present invention, any dosage forms can be optionally employed without limitation. For example, orally administration forms such as tablets, capsules, granules, fine granules, powders or liquids, or parenteral administration forms such as injections, topical products or suppositories can be illustrated, and they can be formulated in the usual way. [0018] When the pharmaceutical compositions of the present invention are employed as a therapeutic agent for gout or hyperuricemia, or a disease such as ischemic-reperfusion injury, inflammatory disease, diabetes, cancer, arteriosclerosis, neurological disease, the dosage used is approximately within the range from 1 mg to 1 g for adults per day depending on the age, sex, body weight and degree of symptoms of each patient. and the daily dose can be divided into several doses. [0019] The present invention is further illustrated by way of the following Examples . In explaining the Examples, tentative names such as "XO-TT53" are used. Example I [0020] 1. Synthesis of pyrazole derivatives A hydrazone, XO-TT462, was prepared by condensation reaction of acetophenone as a starting material and 4-hydrazinobensioic acid. And then, after XO-TT462 was converted into the methyl ester, XO-TT466 was prepared by cyclization by Vilsmeier reaction and formylation. Finally, the end objective XO-TT469 was prepared by cyanation followed by ester hydrolysis in 17% total yields over 5 steps (the following scheme). (Scheme Removed) [0021] A compound wherein the carboxylic acid of XO-TT469 was converted by a tetrazole group was synthesized. The synthesis was basically the same as that for the above XO-TT466 . However, in the last cyanation of XO-TT472, the reaction was conducted without protecting the tetrazole group and XO-TT473 was able to be prepared in a low yield (the following scheme). (Scheme Removed) [0022] A compound wherein a methyl group was introduced into the 5-position of the pyrazole ring of XO-TT469 was synthesized. A pyrazole, XO-TT485, was prepare by condensation reaction of l-phenyl-l,3-butanedione and hydrazine. And a 4-phenyl-carboxylic acid unit was introduced (the following scheme). (Scheme Removed) [0023] Formylation of XO-TT486A was conducted to give XO-TT499 , and the end objective XO-TT507 was able to be prepared through two additional steps (the following scheme). (Scheme Removed) [0024] A derivative wherein the terminal benzene of XO-TT469 was converted into thiophene was synthesized. First, XO-TT500 was prepared by condensation reaction of 2-acetylthiophene and 4-hydrazinobenzoic acid with ethyl esterif ication. And the end objective XO-TT508 was prepared in the usual way (the following scheme). (Scheme Removed) [0025] 2. Shortening of XO-TT469-type synthetic method An objective carboxylic hydrazone, XO-TT520, was prepared by condensation reaction of 2 ' -chloroacetophenone and 4-phenylcarboxylic acid unit under a condition of 2mol/L hydrochloric acid : ethanol =1:5. And Vilsmeier reaction was conducted without protecting the carboxylic acid. As a result, XO-TT522 wherein a pyrazole ring was formed and formylated was able to be prepared. And the end objective XO-TT524 was able to be prepared by cyanation (the following scheme). (Scheme Removed) [0026] An objective carboxylic hydrazone, XO-TT534, was able to be prepared by allowing 4'-methylacetophenone to react in only ethanol as a solvent. And then the end objective XO-TT537 was prepared in the usual way (the following scheme). (Scheme Removed) [0027] The above synthesis 1 is further illustrated in detail as follows. XO-TT-462 To acetophenone (1.00 g, 8.. 32 mmol) were added acetic acid (20 mL) and water (2 mL), and to the mixture stirred was added 4-hydrazinobenzoic acid (1.27 g, 8.32 mmol). The resulting mixture was stirred at 100° C for 21 hours. To the reaction mixture was added water (200 mL), and the solid precipitated by stirring the mixture was collected by filtration and dried in vacuo at 80° C to give XO-TT462 as a brown solid (900 mg, 43% yield). [0028] XO-TT463 XO-TT462 (800 mg, 3.15 mmol) was dissolved in methanol (100 mL), and to the solution was added concentrated sulfuric acid (1 mL) and the mixture was heated for reflux for 30 hours. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The organic layer was dried over anhydrous sodium sulfate and the solvent was evaporated. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 5 : 1 - 3 : 1) to give XO-TT463 as a pale yellow solid (465 mg, 55% yield). [0029] XO-TT466 A mixture of phosphorus oxychloride (0.400 mL) and dimethylf ormamide ( 3 mL) was stirred under a nitrogen atmosphere at 0°C for 30 minutes . To the reaction mixture was addedXO-TT463 (460 mg, 1.72 mmol), and the mixture was stirred at room temperature for 12 hours. To the reaction mixture was added water (200 mL), and the solid precipitated by stirring the mixture was collected by filtration and dried in vacuo at 80° C to give XO-TT466 as a pale yellow solid (456 mg, 87% yield). [0030] XO-TT468 To XO-TT466 (400 mg, 1.31 mmol) were added formic acid (5.0 mL) , sodium formate (177 mg, 2.61 mmol) and hydroxyamine hydrochloride (109 mg, 1.57 mmol), and the mixture was heated for reflux under a nitrogen atmosphere for 45 minutes. To the reaction mixture was added water (150 mL) , and the mixture was stirred and extracted with ethyl acetate (200 mL) . The organic layer was dried over anhydrous sodium sulfate, and the solvent was removed under reduced pressure. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 5 : 1 to 3 : 1) to give XO-TT468 as a pale yellow solid (338 mg, 85% yield). [0031] XO-TT469 XQ-TT468 (330 mg, 1.09 mmol) was dissolved in 1,4-dioxane (20 mL) , and to the solution were added sodium carbonate (577 mg, 5.45 mmol) and water (5 mL). The mixture was stirred at 80° C . To the reaction mixture were added water (150 mL ) , 2mol/L hydrochloric acid (30 mL) , and the mixture was stirred. The precipitated solid was collected by filtration and dried in vacuo to give XO-TT469 as a white solid (306 mg, 97% yield). [0032] 1-phenyl-l,3-butanedione (2.00g, 12.3 mmol) was dissolved in ethanol, and to the solution was added hydrazine monohydrate (1.80 mL, 37.0 mmol) , and the mixture was stirred at 80° C for 3 hours. After about 80% of ethanol in the reaction solution was removed under reduced pressure, water (200 mL) was added to the residue. The precipitated solid was collected by filtration and dried in vacuo at 80° C to give XO-TT485 as a white solid (1.88 g, 97% yield). [0033] XO-TT486A XO-TT485 (300 mg, 1.90 mmol) was dissolved in dimethyl sulfoxide (10 mL) , and to the solution were added 40% potassium fluoride-alumina (600 mg), methyl 4-fluorobenzoate (492 mL, 3.80 mmol) and 18-crown-6 (100 mg, 0.380 mmol). The mixture was stirred at 120° C for 2 days. To the reaction mixture was added water, and the mixture was extracted with ethyl acetate. The residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 10 : 1 to 5 : 1) to give XO-TT486A as a white solid (64.9 mg, 12% yield). [0034] XO-TT500 2-acetylthiophene (1.00 g, 7.93 mmol) was dissolved in ethanol (30 mL), and to the solution were added 4-hydrazinobenzoic acid (1.21 g, 7.93 mmol) and 5 mol/L hydrochloric acid (2 mL). The mixture was stirred at 100° C for 23 hours. To the reaction mixture was added water (200 mL) , and the mixture was extracted with ethyl acetate (200 mL) . The solvent was removed under reduced pressure, and the residue was purified by column chromatography on silica gel (hexane : ethyl acetate = 4 : 1) to give XO-TT500 as a pale yellow solid (781 mg, 34% yield). Example 2 [0035] 1. Synthesis of XO-B327 After a pyrrole compound, XO-B315, was prepared by allowing a-cyanocinnamic acid to react with tosylmethyl-isocyanide (88% yield), XO-B321 was prepared by coupling reaction of methyl 4-fluoro benzoate and XO-B315 (41% yield). And then, the end objective XO-B327 was synthesized by ester hydrolysis (94% yield, the following scheme). (Scheme Removed) [0036] 2. Synthesis of XO-B366 After XO-B348 was prepared by diazonating toluizine and by allowing it to react with ethyl benzoylacetate acid (quantitative yield), a triazole compound, XO-B351, was prepared using copper (I) iodide (89% yield). And then, XO-B358 was prepared by converting the ethoxycarbonyl group into amide (92% yield) and by dehydrating to convert it into a cyano group (88% yield). And then, a mixture of bromide compounds, XO-B362 (5% yield) and XO-B362-2 (8% yield), was prepared by brorninating the methyl group, and the end objective XO-B366 was synthesized by direct hydrolysis (19% yield, the following scheme). (Scheme Removed) [0037] The above synthesis is further illustrated in detail as follows. 1) Synthesis of XO-B315 (Formula Removed) Potassium hydroxide (2.96 g, 45 mmol) was dissolved in methanol (30 mL) , and the solution was cooled in ice. To the solution was added α-cyanocinnamic acid (1.73 g, 10 mmol) , and the mixture was stirred under ice-cooling for 30 minutes. To the react ion mixture was added dropwise a solution of tosylmethyl isocyanide (2.05 g, 10.5 mmol) in dichloromethane (15 mL) for 17 minutes at 5° C or lower, and the mixture was further stirred for an hour under ice-cooling. To the reaction mixture was added water (10 mL) to dissolve insoluble materials, and the mixture was adjusted to pH8 by adding 10% hydrochloric acid. The organic solvent was removed under reduced pressure, and to the residue was added water (20 mL), and the mixture was stirred at room temperature for 30 minutes. The formed solid was collected by filtration, washed with water and dried under reduced pressure at 60° C to give XO-TT315 as a pale brown plate crystal (1.48 g, 88.1% yield). Example 3 [0038] 1. Synthesis of 3-cyanoindole derivatives with a terminal carboxylic acid A basic synthetic method of a derivative with a terminal carboxylic acid is shown in the following scheme. (Scheme Removed) [0039] An objective compound was prepared by (1) formylation of 3-position of the corresponding indole using phosphorus oxychloride in the presence of dimethylformamide (Vilsmeier method), (2) cyanation by dehydrating reaction with hydroxylamine in sodium formate and formic acid, (3) coupling with ethyl 4-fluorobenzoate in the presence of potassium fluoride on almina and 18-crown-6-ether in dimethylsulfoxide and then , (4) hydrolysis with lithium hydroxide in total 4 steps in that order. The results are shown in the following Table 1. In addition, XO-CH146 (R=H) was prepared from the third step using 3-cyanoindole purchased. [0040] [Table 1] (Table Removed) [0041] 2. Synthesis of XO-CH150 XO-CH145 was prepared by coupling of indole-3-carboaldehyde and 4-fluorobenzonitrile in a similar manner to the third step of the above 1. XO-CH147 was prepared by converting XO-CH145 into a tetrazole derivative using sodium azide, followed by cyanation using hydroxylamine to give XO-CH150 (the following scheme). (Scheme Removed) 3. Synthesis of XO-CH151 XO-CH151 was prepared by converting indole-3-caboxylic acid into an acid chloride, amidating it with aqueous ammonia and then, converting to a tetrazole in a similar manner to that of XO-CH150 (the following scheme). (Scheme Removed) [0043] The above syntheses 1 to 3 are further illustrated in detail as follows. 1. Synthesis of XO-CH164 XO-CH155 Under an argon atmosphere, 5-methyl indole (1.04 g, 7.93 mmol) was dissolved in dimethylformamide (10 mL), and to the solution was added dropwise phosphorus oxychloride (2 mL) under ice-cooling, and the resulting mixture was stirred for 1. 5 hours at room temperature. To the reaction mixture was added dropwise an aqueous sodium hydroxide solution (5 g/15 mL) under ice-cooling, and the mixture was heated for reflux for an hour. The reaction mixture was adjusted to pH2 to 3 with concentrated hydrochloric acid under ice-cooling, and then, the solid was collected by filtration and dried at 60" C under reduced pressure to give XO-CH155 as a pale pink solid (1.13 g, 90% yield). [0044] XO-CH158 XO-CH155 (0.600 g, 3.77 mmol) was dissolved in formic acid (6 mL), and to the solution were added hydroxylamine hydrochloride (0.31 g, 4.5 mmol) and sodium formate (0.47 g, 6.9 mmol), and the mixture was hecited for reflux for an hour. To the reaction mixture was added water under ice-cooling, and the mixture was stirred for 1. 5 hours . The solid was collected by filtration and dried 60° C under reduced pressure to give XO-CH158 as a purple solid (0.397 g, 67% yield). [0045] XO-CH161 XO-CH158 (0.387mg, 2.48 mmol) was dissolved in dimethyl sulf oxide (20mL), and to the solution were added ethyl 4-fluoro benzoate (0.36mL, 2. 5 mmol), 40% potassium fluoride on alumina (0 . 38 g) and 18-crown-6-ether (0.07 g, 0.3 mmol) . The mixture was stirred at 120°C overnight and filtered. To the filtrate was added water, and the mixture was extracted with ethyl acetate . The organic layer was washed with water (3 times) and brine, dried over anhydrous magnesium sulfate and filtered. The filtrate was concentrated and dried under reduced pressure. The residue was purified by column chromatography on silica gel (silicagel 50 g, ethylacetate/hexane = 1/6) to giveXO-CH161 as a white solid (0.186 g, 25% yield) . In addition, the fraction containing highly-polar components obtained through the column chromatography was recrystallized with ethyl acetate / hexane to give XO-CH161 as a white solid additionally (0.165 g, 22% yield). [0046] XO-CH164 XO-CH161 (0.186 g, 0.611 mmol) was dissolved in tetrahydrof urari (10 mL) , and to the solution was added a solution of lithium hydroxide monohydrate (0.042g, 0.99 mmol) in water ( 5 mL-) . The.mixture was stirred for 6 hours at room temperature . In an ice-water bath, to the reaction mixture was added water and adjusted to pHl with 2 mol/L hydrochloric acid. The solid was collected by filtration and dried at 60° C under reduced pressure to give XO-CH164 as a white solid (0 .154 g, 91% yield) . [0047] 2. Synthesis of XO-CH146 XO-CH144 XO-CH144 was prepared in a similar manner to that of XO-CH161 as a pale brown solid (0.123 g, 60% yield). [0048] XO-CH146 XO-CH146 was prepared in a similar manner to that of XO-CH164 as a white solid (0.082 g, 81% yield). [0049] 3. Synthesis of XO-CH160 XO-CH154 XO-CH154 was prepared in a similar manner to that of XO-CH155 as a pale yellow solid (2.34 g, 97% yield). [0050] XO-CH156 XO-CH156 was prepared in a similar manner to that of XO-CH158 as a green-gray solid (0.96 g). [0051] XO-CH159 XO-CH159 was prepared in a similar manner to that of XO-CH161 as a white crystal (0.57 g, 32% yield (in 2 steps)). [0052] XO-CH160 XO-CH160 was prepared in a similar manner to that of( XO-CH164 as a white solid (0.453 g. 85% yield). [0053] 4. Synthesis of XO-CH168 XO-CH157 XO-CH157 was prepared in a similar manner to that of XO-CH155 as a pale yellow solid (2.30 g, 95% yield). [0054] XO-CH163 XO-CH163 was prepared in a similar manner to that of XO-CH158 as a green-brown solid (0.354 g, 71% yield). [0055] XO-CH167 XO-CH167 was prepared in a similar manner to that of XO-CH161 as a pale yellow solid (0.373 g, 55% yield). [0056] XO-CH168 XO-CH168 was prepared in a similar manner to that of XO-CH164 as a pale yellow solid (0.235 g, 69% yield). [0057] 5. Synthesis of XO-CH150 XO-CH145 XO-CH145 was prepared in a similar manner to that of XO-CH161 as a pale brown crystal (0.608 g, 72% yield). [0058] XO-CH147 XO-CH145 (0 . 200 g, 0 .811 mmol) was dissolved in 1-methyl-2-pyrrolidone (6 mL), and to the solution were added sodium azide (0.17g, 2. 6 mmol) and triethylamine hydrochloride (0.23 g, 1.7 mmol) . The mixture was stirred for 14 hours at 120° C. To the reaction mixture was added water, and the mixture was adjusted to pH3 with 2mol/L hydrochloric acid in an ice-water bath, and stirred for 30 minutes. The solid was collected by filtration and dried under reduced pressure at 60° C to give XO-CH147 as a brown solid (0.248 g, quantitative yield). [0059] XO-CH150 XO-CH150 was prepared in a similar manner to that of XO-CH158 as a red-brown solid (0.147 g, 69% yield). [0060] 6. Synthesis of XO-CH151 XO-CH148 Indole-3-carboxylic acid (0.494 g, 3.07 mmol) was suspended in dichloromethane (10 mL), and to the suspension were added thionyl chloride ( 0 . 27 mL , 3.7 mmol) and acetonitrile (5 mL). The mixture was stirred for an hour at 60°C, and to the reaction mixture was further added thionyl chloride (0.27 mL, 3.7 rnmol) . The mixture was stirred for an hour. After the solvent of the reaction mixture was evaporated to dryness, the residue was dissolved in acetonitrile (5 mL) . To the solution was added 28% aqueous ammonia (2 mL) in an ice-water bath, and the mixture was stirred for 30 minutes . To the reaction mixture was added water, and the mixture was extracted with ethyl acetate . The organic layer was washed with water (twice) and brine and dried over anhydrous sodium sulf ate and filtered. The filtrate was concentrated and dried under reduced pressure to give XO-CH148 as a pale yellow solid (0.252 g. 51% yield). [0061] XO-CH149 XO-CH149 was prepared in a similar manner to that of XO-CH161 as a pale yellow crystal (0.102 g, 61% yield). [0062] XO-CH151 XO-CH151 was prepared in a similar manner to that of XO-CH147 as a pale yellow solid (0.018 g, 19% yield). Example 4 [0063] 1. Synthesis of indole derivatives 1) Synthesis of 3-cyanoindole derivatives (Scheme Removed) Nine objective compounds were prepared by (1) f ormylation of 3-position of the corresponding indole using phosphorus oxychloride in the presence of dimethylformamide (Vilsmeier method), (2) cyanation by dehydrating reaction with hydroxylamine in sodium formate and formic acid, (3) coupling with ethyl 4-fluorobenzoate in the presence of potassium fluoride on almina and 18-crown-6-ether in dimethyl sulfoxide and then, ( 4) hydrolysis with lithium hydroxide in total 4 steps in that order (the following Table 2). In addition, XO-CH172 and XO-CH183 (R is a 2-methyl group or a 5-methoxy group, respectively) were prepared from the step (2) using the corresponding aldehydes purchased. [0064] [Table 2] (Table Removed) cyanation of XO-CH208 that was prepared by formylation and coupling reaction. And then, XO-CH210 was hydrolyzed to give an objective compound (XO-CH211)(the following scheme). (Scheme Removed) [0066] 2. Synthesis of 7-azaindole derivatives 1) Synthesis of XO-KT10 XO-KT2 was prepared by coupling reaction with ethyl 4-fluorobenzoate. XO-KT5-2 was prepared by using phosphorus oxychloridewithXO-KT2. Subsequently, an aldehyde of XO-KT5-2 was cyanated in the usual way, followed by hydrolysis to give XO-KT10 (the following scheme). (Scheme Removed) [0067] 2) Synthesis of XO-KT16 A 5-bromo derivative of XO-KTIO was prepared from 5-bromo-7-azaindole in reference to the synthetic method as described in the above (1) (the following scheme). (Scheme Removed) [0068] 3) Synthesis of XO-KT18 Similarly, a 6-chloro derivative of XO-KTIO was prepared from 6-chloro-7-azaindole (the following scheme). (Scheme Removed) 4) Synthesis of XO-KT20 A 5-cyano derivative (XO-KT20) was prepared by cyanation of XO-KT14 using zinc cyanide, followed by hydrolysis (the following scheme). (Scheme Removed) [0070] 3. Synthesis of indazole derivatives A iodine was introduced at 3-positon of an indazole ring (the following scheme). An objective compound, XO-KT30, was prepared by converting the iodine into a cyano group using zinc cyanide, followed by coupling in the usual way, and finally by hydrolysis. (Scheme Removed) [0071] The above syntheses 1 to 3 are further illustrated in detail as follows. 1) Synthesis of XO-CH200 XO-CH180 Under an argon atmosphere, 6-methylindole (1.004g, 7.62 mmol) was dissolved in dimethylf ormamide (10 mL) , and to the solution was added phosphorus oxychloride (2 mL) under ice-cooling. The mixture was stirred for 1.5 hours at room temperature. To the reaction mixture was added dropwise an aqueous sodium hydroxide solution (5g/15mL) under ice-cooling. The mixture was heated for reflux for 1. 5 hours . To the reaction mixture was added water under ice-cooling, and the mixture was adjusted to pH3 with concentrated hydrochloric acid. The solid was collected by filtration and dried at 60° C under reduced pressure to give XO-CH180 as a pale brown solid (1.14 g, 94% yield). [0072] XO-CH186 XO-CH180 (1.14 g, 7.16 mmol) was dissolved in formic acid (llmL) , to the solution were added hydroxylamine hydrochloride (0.63 g, 9.1 mmol) and sodium formate (0.90 g, 13 mmol). The mixture was heated for reflux for an hour. To the reaction mixture was added water under ice-cooling, and the mixture was stirred for a while. The solid was collected by filtration and dried 60" C under reduced pressure to give XO-CH186 as a red-black solid (0.85 g, 76% yield). [0073] XO-CH192 XO-CH186 (0.502 mg, 3.21 mmol) was dissolved in dimethyl sulf oxide (25 mL) , and to the solution were added ethyl 4-fluoro benzoate (0. 47 mL, 3. 2 mmol), 40% potassium fluoride on alumina (0.48 g) and 18-crown-6-ether (0.10 g, 0. 38 mmol) . The mixture was stirred at 120°C for 16 hours. The reaction mixture was filtered and water was added to the filtrate. The mixture was extracted with ethyl acetate (twice). The organic layer was washed with water (twice) and brine, dried over anhydrous magnesium sulf ate and filtered. The filtrate was concentrated and dried under reduced pressure. The residue was purified by column chromatography on silica gel (silica gel 50 g, chloroform) to give XO-CH192 as a pale orange solid (0.589 g, 60% yield) . [0074] XO-CH200 XO-CH192 (0.298 g, 0.978 mmol) was dissolved in tetra-hydrofuran, and to the solution were added an aqueous solution of lithium hydroxide monohydrate (0.0702 g, 1.67 mmol) and ethanol. The mixture was stirred for 5 hours at room temperature. In an ice-water bath, to the reaction mixture was added water, and the mixture was adjusted to pHl with 2mol/L hydrochloric acid. The solid was corrected by filtration and dried at 60° C under reduced pressure to give XO-CH200 as a pale pink solid (0.260 g, 96% yield). [0075] 2) Synthesis of XO-CH172 XO-CH169 XO-CH169 was prepared in a similar manner to that of XO-CH186 as a black-brown solid (1.45 g, 74% yield). [0076] XO-CH170 XO-CH170 was prepared in a similar manner to that of XO-CH192 as a pale yellow solid. [0077] XO-CH172 XO-CH172 was prepared in a similar manner to that of XO-CH200 as a pale yellow solid (0.107 g, 74% yield). [0078] 3) Synthesis of XO-CH201 XO-CH184 XO-CH184 was prepared in a similar manner to that of XO-CH180 as a pale orange solid (1.20 g, quantitative yield). [0079] XO-CH189 XO-CH189 was prepared in a similar manner to that of XO-CH186 as a green-brown solid (0.805 g, 75% yield). [0080] XO-CH195 XO-CH195 was prepared in a similar manner to that of XO-CH192 as a pale yellow-green solid (0.304 g, 32% yield). [0081] XO-CH201 XO-CH201 was prepared in a similar manner to that of XO-CH200 as a pale yellow solid (0.261 g, 96% yield). [0082] 4) Synthesis of XO-CH183 XO-CH171 XO-CH171 was prepared in a similar manner to that of XO-CH186 as a black-brown solid (0.790 g, 69% yield). [0083] XO-CH173 XO-CH173 was prepared in a similar manner to that of XO-CH192 as a white solid (0.689 g, 75% yield). [0084] XO-CH183 XO-CH183 was prepared in a similar manner to that of XO-CH200 as a white crystal (0.496 g, 79% yield). [0085] 5) Synthesis of XO-CH199 XO-CH178 XO-CH178 was prepared in a similar manner to that of XO-CH180 as a pale brown solid (1.22 g, 92% yield). [0086] XO-CH179 , XO-CH179 was prepared in a similar manner to that of XO-CH186 as a black-brown solid (1.05 g, 87% yield). [0087] XO-CH190 XO-CH190 was prepared in a similar manner to that of XO-CH192 as a white solid (0.468 g, 52% yield). [0088] XO-CH199 XO-CH199 was prepared in a similar manner to that of XO-CH200 as a white solid (0.234 g, 86% yield). [0089] 6) Synthesis of XO-CH207 XO-CH187 XO-CH187 was prepared in a similar manner to that of XO-CH180 as a brown solid (1.22 g, 92% yield). [0090] XO-CH193 XO-CH193 was prepared in a similar manner to that of XO-CH186 as a green-brown solid (0.413 g, 77% yield). XO-CH203 XO-CH203 was prepared in a similar manner to that of XO-CH192 as a pale yellow solid (0.410 g, 53% yield). [0092] XO-CH207 XO-CH207 was prepared in a similar manner to that of XO-CH200 as a pale yellow solid (0.346 g, 92% yield). [0093] 7) Synthesis of XO-CH209 XO-CH182 XO-CH182 was prepared in a similar manner to that of XO-CH180 as a pale yellow solid (1.20 g, 99% yield). [0094] XO-CH188 XO-CH188 was prepared in a similar manner to that of XO-CH186 as a pale green solid (1.03 g, 88% yield). [0095] XO-CH194 XO-CH194 was prepared in a similar manner to that of XO-CH192 as a pale yellow solid (0.810 g, 89% yield). [0096] XO-CH209 XO-CH209 was prepared in a similar manner to that of XO-CH200 as a white crystal (0.206 g, 74% yield). [0097] 8) Synthesis of XO-CH206 XO-CH185 XO-CH185 was prepared in a similar manner to that of XO-CH180 as a pale yellow solid (0.268 g, 92% yield). [0098] XO-CH191 XO-CH191 was prepared in a similar manner to that of XO-CH186 as a pale blue-green solid (0.213 g, 82% yield). [0099] XO-CH202 XO-CH202 was prepared in a similar manner to that of XO-CH192 as a pale yellow solid (0.191 g, 53% yield). [0100] XO-CH206 XO-CH206 was prepared in a similar manner to that of XO-CH200 as a pale yellow solid (0.155 g, 88% yield). [0101] 9) Synthesis of XO-CH205 XO-CH175 XO-CH175 was prepared in a similar manner to that of XO-CH180 as a yellow solid (1.15 g, 95% yield). [0102] XO-CH176 XO-CH176 was prepared in a similar manner to that of XO-CH186 as a black-brown solid (0.762 g, 78% yield). [0103] XO-CH196 XO-CH196 was prepared in a similar manner to that of XO-CH192 as a pale yellow solid (0.095 g, 10% yield). [0104] XO-CH205 XO-CH205 was prepared in a similar manner to that of XO-CH200 as a white solid (0.075 g, 87% yield). [0105] 10) Synthesis of XO-CH211 XO-CH174 XO-CH174 was prepared in a similar manner to that of XO-CH180 as a pale pink solid (0.549 g, 46% yield). [0106] XO-CH208 XO-CH208 was prepared in a similar manner to that of XO-CH192 as a yellow solid (0.598 g, 59% yield). [0107] XO-CH210 XO-CH210 was prepared in a similar manner to that of XO-CH186 as a pale yellow solid (0.162 g, 27% yield). [0108] XO-CH211 XO-CH211 was prepared in a similar manner to that of XO-CH200 as a pale yellow solid (0.130 g, 88% yield). [0109] 11) Synthesis of XO-KT10 XO-KT2 XO-KT2 was prepared in a similar manner to that of XO-CH192 (1.32 g, 50% yield). [0110] XO-KT5-2 XO-KT2 (560 mg, 2.1 mmol) was dissolved in dimethyl-formamide (4.3 mL), and to the solution was added phosphorus oxychloride (0.8 mL) . The mixture was stirred for 2 hours at room temperature. After the reaction, to the reaction mixture was added an aqueous sodium hydroxide solution (2.7 g/8 mL), and the mixture was heated for reflux for an hour. After the reaction, the reaction mixture was cooled to room temperature, and extracted with ethyl acetate and water added. The organic layer was washed with brine and dried over anhydrous magnesium sulf ate , and the solvent was concentrated under reducedpressure. The residue was purified by column chromatography on silica gel (dichloromethane : methanol = 5:1) to give XO-KT5-2 (374mg, 61% yield). [0111] XO-KT9 XO-KT9 was prepared in a similar manner to that of XO-CH186 (0.354 g, 87% yield). [0112] XO-KT10 XO-KT2(266mg, 1 mmol) was dissolved in a mixed solvent of methanol (4 mL) and water (4 mL), and to the solution was added sodium hydroxide (80mg). The mixture was heated for reflux for 0.5 hour. After the reaction, the reaction mixture was cooled to room temperature, and acetic acid (0.5 mL) was added to the reaction mixture. The precipitate was collected by filtration, washed and dried to give XO-KT6 (230mg, 97% yield). [0113] 12) Synthesis of XO-KT16 XO-KT3 XO-KT3 was prepared in a similar manner to that of XO-CH192 (57% yield). [0114] XO-KT7 XO-KT3 (3.45 g, 10 mmol) was dissolved in dimethylformamide (30.5 mL), and to the solution was added phosphorus oxychloride (3.8mL). The mixture was stirred for 72 hours at room temperature. After the reaction, to the react ion mixture were added an aqueous sodium hydroxide solution (12. 9 g/38 mL) slowly and then water ( 200 mL ). The precipitate was collected by filtration, washed and dried to give XO-KT7 (3.42 g, 92% yield). [0115] XO-KT14 XO-KT3 was prepared in a similar manner to that of XO-CH186 (quantitative yield). [0116] XO-KT16 XO-KT16 was prepared in a similar manner to that of XO-CH200 (0.333 g, 97% yield). [0117] 13) Synthesis of XO-KT18 XO-KT4 XO-KT4 was prepared in a similar manner to that of XO-CH192 (77% yield). [0118] XO-KT8 XO-KT8 was prepared in a similar manner to that of XO-KT7 (74% yield). [0119] XO-KT15 XO-KT15 was prepared in a similar manner to that of XO-CH186 (99% yield). [0120] XO-KT18 XO-KT18 was prepared in a similar manner to that of XO-CH200 (95% yield). [0121] 14) Synthesis of XO-KT20 XO-KT19 Under an argon atmosphere, XO-KT14 (0.370 g, 1 mmol) and zinc cyanide (0.235 g, 2 mmol) were dissolved in dimethylformamide (12 mL), and to the solution was added tetrakis(triphenylphosphine) palladium (0) (0.166 g, 0.1mmol), and the mixture was stirred at 120°C overnight. After the reaction, the reaction mixture was cooled to room temperature, the mixture was extracted with ethyl acetate and water added. The extract was washed with brine, dried over anhydrous magnesium sulfate and concentrated under reduced pressure. The residue was recrystallized from a mixed solvent of ethyl acetate and hexane to give XO-KT19 (0.281 g, 89%). [0122] XO-KT20 XO-KT20 was prepared in a similar manner to that of XO-CH200 (79% yield). [0123] 15) Synthesis of XO-KT30 XO-KT13 Indazole (1.18 g, 10 mmol) was dissolved in dimethylformamide (6 mL) , and to the solution were added iodine (2.8 g, 11 mmol) and potassium hydroxide (2.8 g, 50 mmol) , and the mixture was allowed to react for 0 . 5 hour at room temperature. After the reaction, the reaction mixture was extracted with ethyl acetate and water added. The organic layer was washed with brine and dried over anhydrous magnesium sulfate, and the solvent was concentrated under reduced pressure. The residue was recrystallized from a mixed solvent of ethyl acetate and hexane to give XO-KT13 (1.55 g, 64% yield). [0124] XO-KT23 XO-KT23 was prepared in a similar manner to that of XO-KT19 (41% yield). [0125] XO-KT30 XO-KT24 was prepared in a similar manner to that of XO-KT192, and then XO-KT30 was prepared in a similar manner to that of XO-CH200 (59% yield over 2 steps). Example 5 [0126] A variety of objective derivatives were synthesized according to the following reaction scheme. The results of each synthetic step are shown in the following Table 3. (Table Removed) [0128] The above synthesis is further illustrated in detail as follows. XO-TT538 4 ' -Methoxyacetophenone (1.00 g, 6.66 mmol) was dissolved in ethanol (20 mL) , and to the solution was added 4-hydrazino-benzoic acid (1.06 g, 6.99 mmol). The mixture was stirred at 100° C for 46 hours. To the reaction mixture was added water (250mL), and the mixture was extracted with ethyl acetate (200mL, twice). The organic layer was dried over anhydrous sodium hydroxide , and the solvent was evaporated under reduced pressure . The residue was recrystallized from acetone-water to give XO-TT538 as a pale yellow solid (1.26 g, 67% yield). A mixture of phosphorus oxychloride (0.988 mL) and dimethylformamide (10 mL) was stirred for 30 minutes at 0°C under a nitrogen atmosphere . To the reaction mixture was added XO-TT538 (1.00 g, 3.52 mmol), and the mixture was stirred for 21 hours at room temperature . To the reaction mixture was added water ( 500 mL) . The solid precipitated by stirring the mixture was collected by filtration and dried at 80° C in vacuo to give XO-TT539 as a white solid (646mg, 57% yield). [0130] XO-TT544 To XO-TT539 (300mg, 0.932 mmol) were added formic acid (10 mL), sodium formate (126mg, 1.86 mmol) and hydroxyamine hydrochloride (77.8mg, 1.12 mmol) , and the mixture was stirred at 80° C for 32 hours under a nitrogen atmosphere. To the reaction mixture was added water (100 mL) . The solid precipitated by stirring the mixture was collected by filtration and recrystallized from acetone-water to give XO-TT544 as a white solid (176mg, 59% yield). Example 6 [0131] 1. Synthesis of a-cyanocinnamic acid ethyl ester derivatives An a-cyanocinnamic acid ethyl ester derivative was synthesized using an aldehyde and cyano acetic acid ethyl ester as starting materials by Knoevenagel condensation (the following scheme). The results were shown in the following Table 4. (Formula Removed) [0132] [Table 4] Compound Yield (Table Removed) [0133] In addition, the structure of each compound name listed in Table 4 is as follows. [0134] 2. Synthesis of 3-cyanopyrrole derivatives A 3-cyanopyrrole derivative was prepared by allowing an α-cyanocinnamic acid ethyl ester derivative to react with tosylmethyl isocyanide (the following scheme). After the reaction mixture was neutralized in work-up, the organic solvent was evaporated. The solid precipitated when adding water was collected by filtration. Recystallization was optionally conducted. In case of XO-B376 , after the extraction, the solid was purified by column chromatography and recrystallization. The results were shown in the following Table 5. (Formula Removed) [0135] [Table 5] (Table Removed) [0136] In addition, the structure of each compound name listed in Table 5 is as follows. (Table Removed) [0137] 3. Synthesis of 4-(3-cyano-l-pyrroryl)benzoic acid methyl ester derivatives A 4-(3-cyano-l-pyrroryl)benzoic acid methyl ester derivative was synthesized by coupling of a 3-cyanopyrrole derivative and amethyl 4-f luorobenzoate (the following scheme) . The reaction mixture was treated with 1 mol/L hydrochloric acid, and the precipitated solid was collected by filtration and purified by recrystallization . The results were shown in Table (Formula Removed) [0138] [Table (Table Removed) [0139] In addition, the structure of each compound name listed in Table 6 is as follows. (Table Removed) [0140] 4 . Synthesis of 4- ( 3-cyano-l-pyrroryl )benzoic acid derivatives An end objective 4-(3-cyano-l-pyrroryl)benzoic acid derivative was prepared by hydrolysis of the ester of a 4-(3-cyano-l-pyrroryl) benzoic acid methyl ester derivative (the following scheme) . The results were shown in the following Table 7. (Formula Removed) [0141] [Table 7] (Table Removed) [0142] In addition, the structure of each compound name listed in Table 7 is as follows. (Formula Removed) [0143] 5. Synthesis of XO-B440 XO-B435 was prepared by methylation of tosylmethyl isocyanide (quantitative yield), and then, XO-B437 was synthesized by reaction to form a pyrrole (71% yield). Subsequently, an end objective XO-B440 was prepared by coupling with methyl 4-fluorobenzoate and hydrolysis of the ester of the resultant XO-B439 (42% yields over 2 steps, the following scheme). (Scheme Removed) [0144] The above syntheses 1 to 5 are further illustrated in detail as follows. 1) Synthesis of XO-B363 (Formula Removed) 2-Chlorobenzaldehyde (2.81 g, 20 mmol) and ethyl cyanoacetate ( 2 . 26 g, 20 mmol) were mixed with ethanol ( 30 mL) , and to the mixture was added a few drops of piperidine. The mixture was stirred for 7 hours at room temperature. The reaction mixture was concentrated under reduced pressure, and the residue was separated by column chromatography on silica gel (130 g, dichloromethane/hexane = 1/1) to give XO-B363 as a white needle crystal (4.53 g, 96.24% yield). [0145] 2) Synthesis of XO-B368 (Formula Removed) XO-B363 (2.36 g, 10 mmol) was suspended in ethanol (20 mL) , and the suspension was ice-cooled. After a solution of sodium ethoxide in ethanol (21%wt, 4 . 5 ml,, 12.1 mmol) was added slowly to the mixture, a solution of tosylmethyl isocyanide ( 2 . 05 g, 10. 5 mmol) in dichloromethane (15mL) was added dropwise for 16 minutes at 5° C or lower. The mixture was stirred for 30 minutes under ice-cooling. Insoluble materials were dissolved by adding water (10 mL) to the reaction mixture, and the solution was adjusted to pH8 by adding 10% hydrochloric acid. The organic solvent was removed under reduced pressure, and water (20mL) was added to the residue. The mixture was stirred for 30 minutes at room temperature. The precipitated solid was collected by filtration, washed with water and dried under reduced pressure at 60°C. The obtained crude product was recrystallized from dichloromethane-hexane to give XO-B368 as a pale brown needle crystal (1.86 g, 91.51% yield). [0146] 3) Synthesis of XO-B392 (Formula Removed) XO-B368 (1.22 g, 6 mmol) was dissolved in dimethylformamide (15 mL), and the solution was ice-cooled. After sodium hydride (55% in oil, 315 mg, 7.2 mmol) was added portionwise to the solution, methyl 4-fluorobenzoate (780 fxL, 6 mmol) was added. The mixture was stirred at 150° C for 2 hours under an argon atmosphere. After being cooled, the reaction mixture was poured into cooled Imol/L hydrochloric acid (45 mL). The solid precipitated was collected by filtration, washed with water and dried at 60° C under reduced pressure. The obtained crude product was recrystallized from ethyl acetate to give XO-B392 as a pale brown needle crystal (1.43 g, 70.7% yield). [0147] 4) Synthesis of XO-B397 (Formula Removed) XO-B392 (637mg, 2 mmol) was dissolved in dioxane (10 mL) with heating, and to the solution were added sodium carbonate ( 636mg, 6 mmol) and water (1 mL ) . After the mixture was ref luxed for 14 hours, dioxane (10 mL) and water (3 mL) were added to the reaction mixture. The mixture was further stirred for 72 hours. The reaction mixture was concentrated under reduced pressure. Water (30 mL) was added to the residue, and themixture was dissolved with heating. The solution was adjusted to pH2 by adding 2 mol/L hydrochloric acid. The precipitated solid was collected by filtration, washed with water and dried at 60°C under reduced pressure. The obtained crude product was recrystallized from tetrahydrofuran-water and dried at 60° C under reduced pressure to give XO-B397 as a white needle crystal (595mg, 92.2% yield). [0148] 5) Synthesis (Formula Removed) Tosylmethyl isocyanide (2.93 g, 15 mmol) was dissolved in dichloromethane (30 mL) , and the solution was cooled at 0° C. To the solution were added benzyltriethylammonium chloride ( 683 mg, 3 mmol), methyl iodide (1.85 mL, 30 mmol) and 30% aqueous solution of sodium hydroxide (30 ml,) . The mixture was stirred at 0° C for 3 hours with sealed. To the reaction mixture was added water (150 mL), and the mixture was extracted with dichloromethane (75 mL, twice). The organic layer was dried over sodium sulfate, and concentrated under reduced pressure. Since benzyltriethylammonium chloride remained, the residue was dissolved in dichloromethane (100 mL), and the solution was washed with water (30 mL, twice). The organic layer was dried over sodium sulfate and concentrated under reduced pressure to give XO-B435 as brown oil (3.26 g, quantitative yield). [0149] The following pharmacological studies were performed with the compounds synthesized as described above. 1) Xanthine oxidase inhibitory effect Assay for inhibition of xanthine oxidase was performed in 100 [xmol/L substrate concentration (final concentration), 5 mU/mL enzyme concentration (final concentration) and compounds of the present invention as test compounds which were prepared with xanthine oxidase (from buttermilk; biozyme laboratories) . xanthine (Sigma) and phosphate- buff ered saline (PBS). In addition, all test compounds were frozen for preservation in condition of 20 mmol/L DMSO solution and used for experiments after thawing at need. Method is following: after diluted solution of test compound was added to 90 \iL of 11.1 mU/mL enzyme solution, the mixture was incubated for 10 minutes after mixing. To stat reaction, 100 \iL of 200 jjmol/L substrate solution was added to there, 10 minutes later, the reaction was stopped by addition of 500 µL of 0 . 5 mol/L sulf uric acid, and then absorbance at 283 nm was measured. Final concentration of test compound was a single concentration, 10 µmol/L in single well for initial screening and 6 concentrations, 10, 1 µmol/L, 100, 10, 1 nmol/L, 100 pmol/L in duplicate for assay to calculate 50% inhibitory concentration (IC50) which were used for assay. Percent inhibition was calculated according to the formula described below. Percent inhibition (%) = (A-B) / (A-C) X 100 In formula, A means absorbance in wells without test compound, B means absorbance in wells with test compound, C means absorbance in blank wells. IC50 value was calculated from percent inhibition in each concentration by nonlinear regression method. [0150] 2) UART1 inhibitory effect DMEM containing 10% FBS (supplemented with 0.05% geneticin, Nissui Pharmaceutical Co., Ltd.), HEK293 cells forced to express URAT1 (HCS (Human cell Systems), (Fuji Biomedix)), HBSS as washing buffer and HBSS substituted with Na-gluconate (NaCl in HBSS was substituted with Na-gluconate) were used for assay. [8-14C] uric acid (moravek) was used as an uric acid reagent and added to assay buffer at 20 µmol/L as a final concentration. Compounds of the present invention were used as a test compound, 20 mmol/L stock solution of each test compound(DMSO solution) was diluted appropriately, and then the diluted test compound solution was added to assay buffer at 100 µmol/L as a final concentration including 0.5% final concentration of DMSO. [0151] To prepare assay plates, at first, cells on subculture petri dish were peeled off using treatment of 0 . 05% trypsin-EDTA solution, and then seeded on Biocoat Poly-D-Lysine Cellware 24well plate (BECTON DICKINSON) at a density of 2 x 10s cells/ well and cultured for 2 days. [0152] For the uptake study, at first., culture medium was removed by aspiration and cells were washed twice with HBSS (37°C), then the buffer was replaced with 1 mL of assay buffer (37°C) . Cells were pre-incubated for 10 minutes. And then, the buffer was removed by aspiration and 0.5 mL of radioisotope ligand solution incubated at 37° C was added, then cells were incubated for 5 minutes. After uptake, radioisotope solution was removed by aspiration, and immediately cells were washed three times with ice-cold HBSS, followed by revolving by addition of 0.5 mL of 0.5 mol/L NaOH. Cell lysate solution was transferred to a vial or 24 well plate for Betaplate, and mixed with 0.5 mL of liquid scintillator (Optiphase 'Super Mix' ; Perkin Elmer) . Radioisotope activity was measured (using Betaplate 1450 ). As mean count in control solution not including test compound was 100%, percent inhibition was calculated by determining percent decrease in mean count in solution including test compound from mean count in control solution. [0153] 3) Blood hypouricemic effect Effect of compound of the present invention as a test compound was s tudied on potassium oxonate induced hyperuricemia withmale 7-week-oldSD rats (Charles River Japan) and potassium oxonate (Aldrich) suspended in 1% gum arable solution. Test compound was suspended in 0.5% CMC-Na solution, and then administered orally. Dosing was 10 mg/kg or 50 mg/kg. All volume of administered solution was 10 mL/kg. Potassium oxonate 250 mg/kg was administered to dorsal region of rats subcutaneously, 1 hour later each test compound was administered orally. For control group, only 0.5% CMC-Na solution as a vehicle was administrated. At 2 hours after administration of test compounds or vehicle, blood was collected under ether anesthesia, and serum was separated according to general method. Treated number was 5 for each group. [0154] Measurement of concentration of uric acid was conducted with following prepared reagents. The deproteinization reagent was prepared in the following manner; lOOg of sodium tungstate was added to a 2 L flask, and exactly 75 mL of 85% phosphoric acid and 500 mL of water were added to the flask equipped with a reflux condenser, and heated for an hour. After cooling , the resulting faint yellow-green solution was diluted to 1 L exactly. Sodium carbonate-urea reagent was prepared in the following manner; 14 g of anhydrous sodium carbonate and 14 g of urea were dissolved in water and final volume of the solution was adjusted to 100 mL exactly. Phosphotungstic coloring reagent was prepared in 4-fold dilution of deproteinzation reagent described above with water. UA standard solution (l0mg/dL : Kyokuto pharmaceutical industrial CO. , LTD) was used as an uric acid standard solution, and then serially diluted uric acid standard solution with purified water was also used for standard curve. [0155] Three hundred µL of serum or standard was added to 2.1 mL of purified water, and then 150 µL of deproteination reagent was also added to the solution, followed by mixing. After incubating for 20 minutes, the mixture was centrifuged at 3000 rpm for 10 minutes. Sodium carbonate-urea reagent (0.5 mL) was added to 1. 5 mL of supernatant, and the mixture was incubated for 20 minutes. Next, after addition of 250 µL of coloring reagent, further incubation was carried over 15 minutes. Absorbance at 660 nm was measured, and concentration of uric acid was calculated with standard curve. Percent decrease in concentration of uric acid was calculated by following formula. Percent decrease in concentration of uric acid (%) = (A-B) /AX 100 In formula, A means average of concentration of blood uric acid in control group, B means average of concentration of blood uric acid in test compounds-treated group. [0156] The structural formulas, NMR and MS data and the results from the pharmacological studies of the synthesized compounds of the present invention are shown in the following Tables 8 to 15. [0157] [Table 8] (Table Removed) [0158] [Table 9] (Table Removed) [0159] [Table 10] (Table Removed) [0160] [Table 11] (Table Removed) [0161] ;Table 12] (Table Removed) [0162] [Table 13] (Table Removed) [0163] [Table 14] (Table Removed) [0164] [Table 15] (Table Removed) Industrial Applicability [0165] The nitrogen-containing heterocyclic compounds or the present invention or the pharmaceutically acceptable salts thereof are compounds having a X.O. inhibitory effect and an uricosuric effect. The pharmaceutical compositions of the present invention comprising these compounds as an active ingredient can be expected to be useful as a therapeutic agent for the gout or hyperuricemia, or various diseases such as ischemic-reperf usion disorder, inflammatory disease, diabetes, cancer, arteriosclerosis, neurological disease or the like. CLAIMS 1 . A nitrogen-containing heterocyclic compound represented by the following general formula ( I ) : [ Chem . 1 ] 1 (Formula Removed) wherein Y1 represents N or C(R4); Y2 represents N or C(R5) ; R4 and R5 independently represents an alkyl group which may have a halogen atom, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; one of R1 and R2 represents an haloalkyl group, a cyano group, a carbamoyl. group or a halogen atom; the other of R1 and R2 represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring, an alkoxy group or a heterocyclic group selected from the group consisting of a thienyl, thiazolyl or pyrrolyl group which may be substituted by an alkyl group or a halogen atom; and R3 represents a 5-tetrazolyl group or a carboxy group; and with the proviso that when Y2 represents CR5, Y2 may form a benzene or pyridine ring which may have a haloalkyl group, a halogen atom, a cyano group or an alkoxy group as a substituent together with R2, and some of the neighboring substituents on the ring may form a ring, or a pharmaceutically acceptable salt thereof. 2. A nitrogen-containing heterocyclic compound as claimed in claim 1 represented by the following general formula (I-A) or (I-B): [Chem.2] (Formula Removed) wherein R4a and R5a independently represent a hydrogen atom or an alkyl group; one of Rla and R2a represents a haloalkyl group, a cyano group or a halogen atom; the other of Rla and R2a represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring, an alkoxy group or a heterocyclic group selected from the group consisting of a thienyl, thiazolyl or pyrrolyl group which may be substituted by an alkyl group or a halogen atom; and R3 represents a. 5-tetrazolyl group or a carboxy group, or a pharmaceutically acceptable salt thereof. 3. A nitrogen-containing heterocyclic compound as claimed in claim 2, wherein Rla represents a cyano group, or a pharmaceutically acceptable salt thereof. 4. A nitrogen-containing heterocyclic compound as claimed in claim 3, wherein R2a represents an aryl group which may have a substituent selected from the group consisting of an alkyl group, a haloalkyl group, an alkoxy group and a halogen atom in which some of the substituents may form a ring; an alkoxy group; or a thienyl group which may be substituted by an alkyl group or a halogen atom, or a pharmaceutically acceptable salt thereof. 5. A nitrogen-containing heterocyclic compound as claimed in any of claims 2 to 4, wherein R3 represents a carboxy group, or a pharmaceutically acceptable salt thereof. 6. A nitrogen-containing heterocyclic compound as claimed in claim I represented by the following general formula (I-C) : [Chem.4] (Formula Removed) wherein Y1C represents N or C(R4C) ; Y3 represents N or C(R9); R4C and R9 independently represent an alkyl group, a haloalkyl group, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; R1C represents a cyano group or a carbamoyl group; R6, R7 and R8 independently represent: an alkyl group, a haloalkyl group, a hydrogen atom, a halogen atom, a cyano group or an alkoxy group; or any of R6, R7 and R8 may form a ring together with the neighboring substituent; and R3 represents a 5-tetrazolyl group or a carboxy group, or a pharmaceutically acceptable salt thereof. in claim 6 or 7, wherein R3 represents a carboxy group, or a 7. A nitrogen-containing heterocyclic compound as claimed in claim 6, wherein R1C represents a cyano group, or a pharmaceutically acceptable salt thereof. 8. A nitrogen-containing heterocyclic compound as claimed in claim 6 or 7, wherein R3 represents a a pharmaceutically acceptable salt thereof. 9. A pharmaceutical composition comprising a nitrogen-containing heterocyclic compound as claimed in any * of claims 1 to 8 or a pharmaceutically acceptable salt thereof as an active ingredient. 10 . A pharmaceutical composition as claimed in claim 9 , which is a xanthine oxidase inhibitor. 11. A pharmaceutical composition as claimed in claim 9 or 10, which is an uricosuric agent. 12. A pharmaceutical composition as claimed in any of claims 9 to 11, which is an agent for the treatment of gout or hyperuricemia. 13 . A pharmaceutical composition as claimed in claim 9 , which is an agent for the treatment of ischemic-reperfusion disorder, inflammatory disease, diabetes, cancer, arteriosclerosis or neurological disease.

Documents:

2678 8-1.pdf

2678 8-2 (1).pdf

2678-delnp-2008-Abstract-(08-08-2014).pdf

2678-DELNP-2008-Abstract-101114.pdf

2678-delnp-2008-abstract.pdf

2678-delnp-2008-Claims-(08-08-2014).pdf

2678-DELNP-2008-Claims-101114.pdf

2678-delnp-2008-claims.pdf

2678-delnp-2008-Correspondence Others-(07-08-2014).pdf

2678-delnp-2008-Correspondence Others-(08-08-2014).pdf

2678-delnp-2008-Correspondence Others-(21-07-2014).pdf

2678-DELNP-2008-Correspondence-101114.pdf

2678-delnp-2008-correspondence-others.pdf

2678-delnp-2008-description (complete).pdf

2678-DELNP-2008-Form 2(Title Page)-101114.pdf

2678-delnp-2008-form-1.pdf

2678-DELNP-2008-Form-18.pdf

2678-delnp-2008-form-2-(08-08-2014).pdf

2678-delnp-2008-form-2.pdf

2678-delnp-2008-Form-3-(21-07-2014).pdf

2678-delnp-2008-form-3.pdf

2678-delnp-2008-form-5.pdf

2678-delnp-2008-GPA-(08-08-2014).pdf

2678-DELNP-2008-GPA-101114.pdf

2678-DELNP-2008-OTHERS-101114.pdf

2678-delnp-2008-pct-210.pdf

2678-delnp-2008-pct-304.pdf

abstract.jpg